- Home
- GENK vs SLGL Comparison
GENK vs SLGL Comparison
Compare GENK & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | SLGL |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | Israel |
| Employees | 2700 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 247.1M |
| IPO Year | 2023 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GENK | SLGL |
|---|---|---|
| Price | $2.23 | $73.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.50 | ★ $110.00 |
| AVG Volume (30 Days) | 18.4K | ★ 29.7K |
| Earning Date | 05-13-2026 | 05-22-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $7.48 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.43 | $6.91 |
| 52 Week High | $4.98 | $97.97 |
Technical Indicators
Market Signals| Indicator | GENK | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 50.17 |
| Support Level | $1.53 | $66.40 |
| Resistance Level | $2.30 | $81.64 |
| Average True Range (ATR) | 0.18 | 6.63 |
| MACD | 0.00 | 0.25 |
| Stochastic Oscillator | 69.29 | 49.90 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.